The Motley Fool
24 Sept 2026, 23:57 UTC · 3h ago
Verdict
Headline takes no side. We score IOVA +0.90 across two claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Goldman Sachs resumed coverage of Iovance Biotherapeutics on Thursday with a buy rating and a price target of $15 per share.
Newresumed coverage... on Thursday
So whatThe target implies a 39% upside from the current price of $10.80.
More positive than 93% of claims this week
Iovance's drug Amtagvi generated $91 million in sales and treated 150 patients during the second quarter.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced incited the company's second-quarter performance
So whatScaling this quarterly run rate suggests an annualized revenue baseline of ~$364M.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Goldman Sachs resumed coverage with a 'buy' rating and a price target of $15, citing strong sales and demand for its drug Amtagvi.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
—
IOVA hasn't traded since this ran. Last close $10.80 (Sep 24); the reaction starts at the next open.
IOVA chart →
